PDX Pharma received the USPTO’s Notice of Allowance for the patent application on its core nanoparticle technology (Pdx-NP)

PDX Pharma has received the USPTO’s Notice of Allowance for the patent application US 15/429,971 on its core nanoparticle technology (Pdx-NP) encompassing “Compositions” and “Method of Use” claims. The patent should be issued shortly. The technology is a joint invention of PDX Pharma and OHSU. It was first reported as a cover article in Advanced Functional Materials in 2015. This technology is exclusively licensed to PDX Pharmaceuticals.